HC Wainwright restated their buy rating on shares of Aytu Bioscience Inc (NASDAQ:AYTU) in a research report report published on Thursday morning. HC Wainwright currently has a $9.00 price objective on the stock.
Separately, Rodman & Renshaw started coverage on shares of Aytu Bioscience in a research note on Monday. They issued a buy rating and a $9.00 price objective for the company.
Shares of Aytu Bioscience (NASDAQ:AYTU) traded down 5.88% on Thursday, hitting $3.20. The company had a trading volume of 1,400 shares. The company’s market cap is $16.22 million. The company has a 50 day moving average of $3.64 and a 200-day moving average of $4.79. Aytu Bioscience has a 12-month low of $3.01 and a 12-month high of $57.00.
About Aytu Bioscience
Aytu Bioscience, Inc, formerly Rosewind Corporation, is a healthcare company. The Company is focused on developing treatments for urological and related conditions. The Company’s pipeline of products includes Zertane, and Zertane and a phosphodiesterase type 5 (PDE-5). The Company is conducting Phase III clinical development for its lead therapeutic candidate Zertane, an orally disintegrating tablet (ODT) formulated for the treatment of premature ejaculation (PE).
Receive News & Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.